Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | New pivotal study using photobiomodulation in Alzheimer’s treatment

Photobiomodulation (PBM) therapy, previously known as low-level laser therapy (LLLT), is the application of light – typically in the red and near-infrared spectra – to promote tissue repair and reduce inflammation. PBM therapy primarily targets the cytochrome C complex and can increase ATP production, modulate reactive oxygen species, and restore normal cellular function therefore preventing apoptosis. Jacques Touchon, MD, PhD, University Hospital of Montpellier, Montpellier, France, explains how PBM, specifically brain-gut PBM, is being investigated in the treatment of Alzheimer’s disease (AD). Preliminary data from mouse models demonstrated that PBM improved long- and short-term memory and normalized levels of amyloid-β 42, tau, oxidative stress, and neuroinflammation. This data was used to support a randomized, double-blind, sham-controlled pilot study in which 53 patients with mild-to-moderate AD were enrolled. PBM was administered using the REGEnLIFE RGn600 medical device and was concluded to be safe and well tolerated (44% of patients experienced adverse effects and this was balanced between trial arms). Prof. Touchon presents the design of a new, larger study, named LIGHT4LIFE, which will investigate the efficacy of PBM therapy on patient cognition as measured using the ADAS-Cog score. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Prof. Touchon reports the following disclosures:
-REGEnLIFE stockholder